

Jordi Esteve

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1546997/publications.pdf>

Version: 2024-02-01

244
papers

9,850
citations

53794

45
h-index

42399

92
g-index

248
all docs

248
docs citations

248
times ranked

8773
citing authors

#	ARTICLE	IF	CITATIONS
1	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
2	Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2355-2362.	2.8	519
3	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , 2003, 103, 1237-1243.	1.4	395
4	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , 2008, 111, 3395-3402.	1.4	303
5	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i> , 2009, 113, 775-783.	1.4	279
6	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.	1.4	278
7	Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 735-741.	1.6	251
8	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013, 121, 2734-2738.	1.4	246
9	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. <i>Haematologica</i> , 2010, 95, 589-596.	3.5	240
10	Treatment of High-Risk Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1595-1604.	1.6	227
11	Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. <i>British Journal of Haematology</i> , 1997, 97, 635-640.	2.5	164
12	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. <i>Haematologica</i> , 2010, 95, 87-95.	3.5	164
13	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 976-984.	2.5	163
14	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i> , 2008, 111, 1078-1084.	1.4	156
15	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008, 112, 3130-3134.	1.4	154
16	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 2941-2951.	4.1	140
17	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 392-399.	3.5	139
18	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132

#	ARTICLE	IF	CITATIONS
19	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2006, 107, 4563-4569.	1.4	130
20	High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma. <i>Cancer</i> , 2008, 113, 117-125.	4.1	122
21	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	1.4	112
22	Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 224-234.	3.5	108
23	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	2.4	106
24	Extramedullary multiple myeloma escapes the effect of thalidomide. <i>Haematologica</i> , 2004, 89, 832-6.	3.5	100
25	All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 3490-3493.	1.4	98
26	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
27	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. <i>Haematologica</i> , 2009, 94, 1242-1249.	3.5	93
28	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	1.4	93
29	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
30	How I treat refractory CLL. <i>Blood</i> , 2006, 107, 1276-1283.	1.4	85
31	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	2.5	82
32	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. <i>Molecular Therapy</i> , 2021, 29, 636-644.	8.2	80
33	“Lymphoid” blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. <i>British Journal of Haematology</i> , 1998, 100, 129-134.	2.5	79
34	The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. <i>Oncotarget</i> , 2015, 6, 31613-31627.	1.8	78
35	Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 3872-3879.	1.6	74
36	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2001, 113, 422-424.	2.5	73

#	ARTICLE	IF	CITATIONS
37	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 1810-1822.	3.5	64
38	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 570-570.	1.4	64
39	Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status. <i>Cancer</i> , 2013, 119, 1660-1668.	4.1	63
40	Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. <i>PLoS ONE</i> , 2018, 13, e0199531.	2.5	60
41	Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience. <i>European Journal of Haematology</i> , 2007, 78, 290-296.	2.2	59
42	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 519-530.	2.4	54
43	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	54
44	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	2.4	53
45	Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 171, 57-64.	1.0	52
46	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
47	Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCHR) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. <i>British Journal of Haematology</i> , 2015, 169, 188-198.	2.5	49
48	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	1.4	48
49	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. <i>Clinical Hematology International</i> , 2019, 1, 58.	1.7	46
50	Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. , 1999, 189, 288-293.		44
51	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1406-1414.	2.0	44
52	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , 2018, 132, 2736-2736.	1.4	44
53	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , 2017, 10, 20.	17.0	43
54	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 256-262.	3.5	42

#	ARTICLE	IF	CITATIONS
55	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	1.8	40
56	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	4.1	40
57	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020, 26, 6475-6482.	7.0	40
58	Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2556-2562.	3.0	39
59	A phase II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 763-772.	1.8	39
60	41BB-based and CD28-based CD123-redireceted T-cells ablate human normal hematopoiesis in vivo. , 2020, 8, e000845.		37
61	The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. <i>European Journal of Haematology</i> , 1998, 60, 101-105.	2.2	36
62	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	2.4	36
63	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	2.4	36
64	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	3.5	35
65	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018, 2, 2127-2135.	5.2	34
66	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017, 102, 2134-2140.	3.5	33
67	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	2.4	32
68	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	7.0	32
69	Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. <i>European Journal of Haematology</i> , 2006, 77, 486-492.	2.2	30
70	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018, 124, 2134-2141.	4.1	30
71	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , 2022, 6, 1278-1295.	5.2	29
72	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <i>British Journal of Haematology</i> , 2020, 191, 52-61.	2.5	28

#	ARTICLE	IF	CITATIONS
73	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. <i>PLoS ONE</i> , 2016, 11, e0150637.	2.5	28
74	Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial. <i>Journal of Cardiac Failure</i> , 2011, 17, 643-648.	1.7	26
75	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. <i>Blood Advances</i> , 2022, 6, 1193-1206.	5.2	26
76	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. <i>Annals of Hematology</i> , 2014, 93, 1695-1703.	1.8	25
77	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Annals of Hematology</i> , 2019, 98, 2389-2398.	1.8	24
78	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1944-1952.	7.2	23
79	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2015, 126, 863-863.	1.4	23
80	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	7.2	23
81	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. <i>Cancer</i> , 2001, 91, 1557-1562.	4.1	22
82	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€TD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 736-744.	4.1	21
83	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	1.3	21
84	Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 5395-5402.	5.2	21
85	The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 45-46.	1.4	20
86	PLZF-RAR \pm , NPM1-RAR \pm , and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. <i>Cancers</i> , 2020, 12, 1313.	3.7	20
87	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 248-255.	3.5	19
88	Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells. <i>EBioMedicine</i> , 2019, 47, 221-234.	6.1	19
89	Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols. <i>Blood</i> , 2006, 108, 1503-1503.	1.4	19
90	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richterâ€™s Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 828471.	2.8	19

#	ARTICLE	IF	CITATIONS
91	Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 256-265.	3.5	18
92	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. <i>Journal of Medical Genetics</i> , 2020, 57, 258-268.	3.2	18
93	Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed <i>FLT3</i> -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. <i>Blood</i> , 2021, 138, 700-700.	1.4	18
94	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
95	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 789-796.	4.1	17
96	Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1723-1730.	3.5	17
97	Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e801-e809.	0.4	17
98	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degradator, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. <i>Blood</i> , 2019, 134, 232-232.	1.4	17
99	High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. <i>Leukemia Research</i> , 2014, 38, 874-881.	0.8	16
100	Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 43-46.	1.8	16
101	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2394-2404.	1.3	16
102	Allogeneic stem cell transplantation in AML with <i>t(6;9)(p23;q34);DEK-NUP214</i> shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020, 189, 920-925.	2.5	16
103	Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. <i>Leukemia Research</i> , 2015, 39, 1146-1153.	0.8	15
104	Characteristics and outcome of patients with acute myeloid leukaemia and <i>t(8;16)(p11;p13)</i> : results from an International Collaborative Study*. <i>British Journal of Haematology</i> , 2021, 192, 832-842.	2.5	15
105	Prognostic impact of <i>DNMT3A</i> mutation in acute myeloid leukemia with mutated <i>NPM1</i> . <i>Blood Advances</i> , 2022, 6, 882-890.	5.2	15
106	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86.	2.2	14
107	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. <i>American Journal of Clinical Pathology</i> , 2015, 144, 484-492.	0.7	13
108	Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1575-1581.	2.8	13

#	ARTICLE	IF	CITATIONS
109	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	2.4	13
110	Relatively favorable outcome after allogeneic stem cell transplantation for <i>BCR-ABL1</i> -positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2018, 93, 31-39.	4.1	13
111	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2319-2328.	1.8	13
112	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	1.2	13
113	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016, 101, e34-e37.	3.5	12
114	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	1.3	12
115	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020, 34, 1144-1153.	7.2	12
116	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. <i>European Journal of Haematology</i> , 2020, 105, 138-147.	2.2	12
117	Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585.	7.2	12
118	Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI). <i>Transfusion and Apheresis Science</i> , 2021, 60, 103011.	1.0	12
119	Risk of relapse and clinicopathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. <i>European Journal of Haematology</i> , 1998, 61, 59-64.	2.2	11
120	Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 28-34.	2.3	11
121	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	6.2	11
122	Factors associated with the clinical outcome of patients with relapsed/refractory CD19 ⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
123	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2452.	2.8	10
124	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 414-423.	3.5	10
125	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 40-50.	4.1	10
126	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617.	2.7	10

#	ARTICLE	IF	CITATIONS
127	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. <i>Blood</i> , 2021, 138, 4669-4669.	1.4	10
128	The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 529-543.	1.7	9
129	Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncologist</i> , 2015, 20, 50-55.	3.7	9
130	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. <i>Leukemia Research</i> , 2017, 63, 85-89.	0.8	9
131	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2018, 68, 79-84.	0.8	9
132	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. <i>Annals of Hematology</i> , 2019, 98, 2467-2483.	1.8	9
133	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	1.3	9
134	Mutational profile of ZBTB16-positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	2.8	9
135	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2015, 126, 1333-1333.	1.4	9
136	Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) <i>mIDH1</i> acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 7006-7006.	1.6	8
137	MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7063-TPS7063.	1.6	8
138	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2022, 57, 1556-1563.	2.4	8
139	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 322-327.	2.8	7
140	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 282-294.	4.1	7
141	Allogeneic stem cell transplant in patients with acute myeloid leukemia and Karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer Medicine</i> , 2021, 10, 23-33.	2.8	7
142	Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with <i>mIDH1</i> Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 698-698.	1.4	7
143	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. <i>Blood</i> , 2020, 136, 40-42.	1.4	7
144	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 489.e1-489.e9.	1.2	7

#	ARTICLE	IF	CITATIONS
145	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	2.8	6
146	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1295-1303.	2.4	6
147	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	2.5	6
148	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	2.2	6
149	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020, 55, 2244-2253.	2.4	6
150	Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1135-1141.	4.1	6
151	UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. <i>Leukemia</i> , 2020, 34, 2925-2933.	7.2	6
152	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , 2021, 35, 2232-2242.	7.2	6
153	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2445-2453.	2.4	6
154	Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. <i>American Journal of Hematology</i> , 2022, 97, 731-739.	4.1	6
155	Early B-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness. <i>British Journal of Haematology</i> , 2019, 185, 755-757.	2.5	5
156	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 609-609.	1.4	5
157	Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based Model Using The Data Set of The Acute Leukemia Working Party (ALWP) Of The EBMT. <i>Blood</i> , 2013, 122, 409-409.	1.4	5
158	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. <i>Blood</i> , 2021, 138, 3677-3677.	1.4	5
159	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. <i>Cancer Cell International</i> , 2015, 15, 122.	4.1	4
160	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2018, 132, 708-708.	1.4	4
161	Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2008, 112, 793-793.	1.4	4
162	Prognostic Significance Of a 4-Microrna Signature Targeting JAK2 In Classical Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 629-629.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Piwirna-651 Expression Influences Treatment Response and Impacts Survival in Classical Hodgkin Lymphoma Patients through Regulation of ABCC5. <i>Blood</i> , 2014, 124, 134-134.	1.4	4
164	At-Home Management of Adult Patients Following Consolidation Chemotherapy for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3692-3692.	1.4	4
165	Ponatinib and Chemotherapy in Adults with <i>De Novo</i> Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponafil Clinical Trial. <i>Blood</i> , 2021, 138, 1230-1230.	1.4	4
166	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 175.	6.2	3
167	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mLDH1 Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2351-2351.	1.4	3
168	Cytogenetic risk classification maintains its prognostic significance in transplanted <i>FLT3↝</i> mutated acute myeloid leukemia patients: On behalf of the <scp>acute leukemia working party</scp>/<scp>European society of blood and marrow transplantation</scp>. <i>American Journal of Hematology</i> , 2022, 97, 274-282.	4.1	3
169	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.8	3
170	Romiplostim for the treatment of glioblastoma-related paraneoplastic autoimmune thrombocytopenia refractory to conventional therapy. <i>Annals of Hematology</i> , 2016, 95, 665-666.	1.8	2
171	Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. <i>Leukemia and Lymphoma</i> , 2019, 60, 2720-2732.	1.3	2
172	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1047-1055.	2.4	2
173	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 461-469.	2.4	2
174	Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case–Control Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 955-970.	4.0	2
175	Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Preliminary Results of Ponafil Clinical Trial. <i>Blood</i> , 2019, 134, 3874-3874.	1.4	2
176	Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease. <i>Blood</i> , 2019, 134, 289-289.	1.4	2
177	The Influence of Monosomal Karyotype On Survival in Patients with Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Survey On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011, 118, 158-158.	1.4	2
178	Evaluation Of Two Prognostic Scoring Systems For Chronic Myelomonocytic Leukemia (CMML): CMML-Specific Prognostic Scoring System (CPSS) and MD Anderson Prognostic Score (MDAPS) In A Series Of 122 Cases Of De Novo CMML. <i>Blood</i> , 2013, 122, 2810-2810.	1.4	2
179	Prediction of Allogeneic HSCT Related Mortality in Acute Leukemia: Exploring Boundaries of Prediction through Machine Learning Based Modeling. a Data Mining Study from the Acute Leukemia Working Party (ALWP) of the EBMT. <i>Blood</i> , 2014, 124, 2568-2568.	1.4	2
180	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 112-112.	1.4	2

#	ARTICLE	IF	CITATIONS
181	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 324-324.	1.4	2
182	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. <i>Leukemia and Lymphoma</i> , 2022, 63, 1993-1996.	1.3	2
183	Bone marrow <i>VEGFC</i> expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. <i>Leukemia and Lymphoma</i> , 2018, 59, 2383-2393.	1.3	1
184	Prognostic Factors in AML. <i>Hematologic Malignancies</i> , 2021, , 127-175.	0.2	1
185	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 2038-2038.	1.4	1
186	Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Updated Results of the Spanish PETHEMA LPA99 Trial Using ATRA and Anthracycline Monochemotherapy.. <i>Blood</i> , 2007, 110, 590-590.	1.4	1
187	A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement. <i>Blood</i> , 2010, 116, 230-230.	1.4	1
188	Allogeneic Hematopoietic Stem-Cell Transplantation In Early Phase Might Overcome the Adverse Prognosis of Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34)/DEK-NP214(CAN) Rearrangement. A Retrospective Analysis From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2010, 116, 3501-3501.	1.4	1
189	Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. <i>Blood</i> , 2015, 126, 2723-2723.	1.4	1
190	Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 63-63.	1.4	1
191	<i>KMT2A-CBL</i> rearrangements in acute leukemias: clinical characteristics and genetic breakpoints. <i>Blood Advances</i> , 2021, 5, 5617-5620.	5.2	1
192	Intensive Immunochemotherapy In Patients With B-Cell Lymphoma, Unclassifiable (B-UCL), With Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Burkitt Lymphoma (BL): A Comparison With BL Patients Treated With The Same Protocol In The Pethema-Burkimab-04 Trial. <i>Blood</i> , 2013, 122, 1793-1793.	1.4	1
193	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 1230-1230.	1.4	1
194	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2018, 132, 248-248.	1.4	1
195	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). <i>Blood</i> , 2018, 132, 1385-1385.	1.4	1
196	Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients. <i>Blood</i> , 2019, 134, 2584-2584.	1.4	1
197	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. <i>Blood</i> , 2021, 138, 2920-2920.	1.4	1
198	Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment. <i>Blood</i> , 2020, 136, 29-30.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	1
200	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. <i>Leukemia Research</i> , 2021, 101, 106492.	0.8	0
201	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. <i>Blood</i> , 2004, 104, 2054-2054.	1.4	0
202	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. <i>Blood</i> , 2005, 106, 3009-3009.	1.4	0
203	Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. <i>Blood</i> , 2006, 108, 2010-2010.	1.4	0
204	A Prospective Study on the Feasibility of Related and Unrelated Donor Search and Hematopoietic Cell Transplantation for Adults with Acute Leukemia at 31 European Transplant Centers. <i>Blood</i> , 2008, 112, 2385-2385.	1.4	0
205	Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2611-2611.	1.4	0
206	Impact of the Presence of An Internal Tandem Duplicate of FLT3 Receptor (ITD) on the Outcome of Adult Patients with Acute Myelocytic Leukemia (AML) Autografted In First Remission (CR1)Norbert-Claude Gorin, Myriam Labopin, Jordi Esteve, and Mohamad Mohty, on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 3556-3556.	1.4	0
207	Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia (AML) with 11q23 (MLL) Rearrangement (MLL-r AML). A Retrospective Analysis From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2011, 118, 498-498.	1.4	0
208	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT., <i>Blood</i> , 2011, 118, 4107-4107.	1.4	0
209	Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT. <i>Blood</i> , 2013, 122, 4565-4565.	1.4	0
210	DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA. <i>Blood</i> , 2013, 122, 1339-1339.	1.4	0
211	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2577-2577.	1.4	0
212	Chemotherapy Dose Adjustment For Obese Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Survey On Behalf Of The ALWP Of The EBMT. <i>Blood</i> , 2013, 122, 4535-4535.	1.4	0
213	Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens. <i>Blood</i> , 2013, 122, 3922-3922.	1.4	0
214	Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma. <i>Blood</i> , 2013, 122, 1422-1422.	1.4	0
215	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients â€” A Report From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013, 122, 921-921.	1.4	0
216	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. <i>Blood</i> , 2014, 124, 1003-1003.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model. <i>Blood</i> , 2014, 124, 4660-4660.	1.4	0
218	Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome. <i>Blood</i> , 2014, 124, 4636-4636.	1.4	0
219	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. <i>Blood</i> , 2014, 124, 3798-3798.	1.4	0
220	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 4364-4364.	1.4	0
221	Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD). <i>Blood</i> , 2015, 126, 1672-1672.	1.4	0
222	Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2015, 126, 155-155.	1.4	0
223	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 2021-2021.	1.4	0
224	Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 196-196.	1.4	0
225	Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. <i>Blood</i> , 2015, 126, 2511-2511.	1.4	0
226	Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. <i>Blood</i> , 2015, 126, 2514-2514.	1.4	0
227	Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4331-4331.	1.4	0
228	Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study. <i>Blood</i> , 2017, 130, 907-907.	1.4	0
229	Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Adult Patients with t(4;11)(q21;q23) <i>KMT2A/AFF1 (MLL/AF4)</i> B-Acute Lymphoblastic Leukemia in First Complete Remission (CR1): Favorable Outcome of Patients with Negative Minimal Residual Disease (MRD) Status at Transplant. a Report from the Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation (ALWP-EBMT). <i>Blood</i> , 2017, 130, 669-669.	1.4	0
230	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2017, 130, 852-852.	1.4	0
231	Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with De Novo Mutated NPM1 (NPM1mut) acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1492-1492.	1.4	0
232	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. <i>Blood</i> , 2018, 132, 3103-3103.	1.4	0
233	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , 2018, 132, 4299-4299.	1.4	0
234	FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 609-609.	1.4	0

#	ARTICLE	IF	CITATIONS
235	The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT. <i>Blood</i> , 2018, 132, 4639-4639.	1.4	0
236	Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 2760-2760.	1.4	0
237	Design and <i>in Vitro</i> Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4799-4799.	1.4	0
238	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021, 138, 3952-3952.	1.4	0
239	Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. <i>Blood</i> , 2021, 138, 3925-3925.	1.4	0
240	Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1Å– 109/L Should be Classified As CMML. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
241	Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project). <i>Blood</i> , 2020, 136, 32-33.	1.4	0
242	Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). <i>Blood</i> , 2020, 136, 31-32.	1.4	0
243	Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
244	Emergence of <i>NPM1</i> Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with <i>NPM1</i> Mutation: Proposed Mechanisms of Clonal Evolution. <i>Blood</i> , 2020, 136, 39-40.	1.4	0